Obermatt
See Similar Stocks →

Flags

Financial distress

Genfit

PAR:GNFT · FR0004163111
BiotechnologySmall

360

32
Profit price58
Owner Earnings Yield1
Dividend Yield1
Price/Sales65
EV / Gross Profit47
Price/Book97
Return on Capital44
Cash Return on Capital10
EBIT Margin33
Gross Profitability78
Accruals82
Owner Earnings Margin40
Sales growth66
Profit growth66
Reinvestment77
Price momentum90
Debt load12
Refinancing75
Debt Payback1
Liquidity24
Analyst ratings100
Opinion Changes50
Price Target Upside11
Market mood65
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Genfit doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryFrance
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded1999
Employees179
Websitegenfit.fr
ISINFR0004163111
Last UpdateApr 2, 2026
Indices
CAC All (France)
Themes
Chronic DiseasesHealth DiagnosticsGastroenterologyCentral Nervous SystemInflammationOncologyHepatologyBiopharmaBiotechnologyHealth Care

Description

Genfit S.A. (GENFIT) operates as a late-stage biopharmaceutical company. The company is a biopharmaceutical group conducting preclinical and clinical research and development of drug candidates and diagnostic technologies and dedicated to improving…

Analysis

Middle-of-the-road

Genfit S.A. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
91
2026

All-time high

91

Jun 2026

All-time low

70

Mar 2026

Average rank

81

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
65
—
—
—
Price/Earnings
11
—
—
—
Price/Book
97
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
63
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Genfit with its peers
BB Biotech
SWX:BION
96
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BioNTech
NSQ:BNTX
11
CountryGermany
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Inventiva
PAR:IVA
16
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Grifols
MCE:GRF
61
CountrySpain
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Zealand Pharma
CPH:ZEAL
78
CountryDenmark
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →